The mechanism underlying cancer-specific telomerase activation/TERT expression has been extensively studied, and recent findings showed that HCC tumors frequently bear activating mutations in the TERT proximal promoter (−124 and −146 bp from the ATG, so-called C228T and C250T, respectively) [2, 8–20]. This evidence concerns the gene TERT and cancer.